148 related articles for article (PubMed ID: 28196206)
1. Regression of Iris Metastasis After Systemic Treatment With Melanoma-Targeted Therapy.
Fonseca C; Fernandes J; Proença R
JAMA Ophthalmol; 2017 Feb; 135(2):e165462. PubMed ID: 28196206
[No Abstract] [Full Text] [Related]
2. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
[No Abstract] [Full Text] [Related]
4. Dress syndrome secondary to different combinations of targeted therapy (iBRAF + iMEK).
Robert M; Jantzem H; Etienne M; Misery L
Eur J Dermatol; 2020 Jun; 30(3):303-304. PubMed ID: 32666930
[No Abstract] [Full Text] [Related]
5. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
[No Abstract] [Full Text] [Related]
6. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
7. Sustained complete remission of metastatic melanoma on targeted therapy and rituximab for rheumatoid arthritis.
Reschke R; Kohlmann J; Baerwald C; Ziemer M
J Dtsch Dermatol Ges; 2019 Jun; 17(6):638-639. PubMed ID: 30947390
[No Abstract] [Full Text] [Related]
8. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.
Engel S; Luessi F; Henning B; Bittner S; Loquai C; Zipp F
Ann Oncol; 2019 Jun; 30(6):1014-1016. PubMed ID: 30911762
[No Abstract] [Full Text] [Related]
10. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
Devic P; Amini-Adle M; Camdessanché JP; Dalle S
Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
[No Abstract] [Full Text] [Related]
11. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
12. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
13. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
14. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
15. Cobimetinib (Cotellic) for metastatic melanoma.
Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
[No Abstract] [Full Text] [Related]
16. Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A; Thomas L
Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
[TBL] [Abstract][Full Text] [Related]
17. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.
Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT
J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754
[No Abstract] [Full Text] [Related]
18. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
19. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
20. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
[Next] [New Search]